Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of the association of
Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma
patients over age 65 or those under 65 years who refuse or are not eligible for high dose
therapy. This association might further increase the response rate achieved by the standard
oral MP regimen.